Form 4: Pfizer Inc. Discloses Disposition of Cerevel Therapeutics Holdings Shares Following AbbVie Merger

Pfizer Inc. reports the disposition of its Cerevel Therapeutics Holdings shares following the completion of the merger with AbbVie on August 1, 2024, where each share was converted to $45.00 in cash.

Summary

• This Form 4 filing reports the change in beneficial ownership of Cerevel Therapeutics Holdings, Inc. (CERE) shares by Pfizer Inc.
• The transaction occurred on August 1, 2024, following the merger between Cerevel Therapeutics Holdings, Inc. and AbbVie Inc.
• As a result of the merger, each outstanding share of Cerevel Therapeutics Holdings common stock was converted into the right to receive $45.00 in cash.
• Pfizer Inc. disposed of 27,349,211 shares of Cerevel Therapeutics Holdings common stock at a price of $45.00 per share.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a completed merger transaction. There are no explicit positive or negative implications for Pfizer from this filing alone.

Future Outlook

Not applicable, as the document primarily reports a completed transaction.

Industry Context

This announcement reflects the completion of a significant merger in the pharmaceutical industry, where AbbVie acquired Cerevel Therapeutics to expand its portfolio. Such acquisitions are common in the industry as companies seek to bolster their pipelines and market presence.

Comparison to Industry Standards

• Mergers and acquisitions are a common strategy in the pharmaceutical industry for growth and diversification.
• The $45 per share acquisition price reflects the valuation of Cerevel Therapeutics at the time of the agreement.
• Comparable transactions include other acquisitions of biotech companies with promising drug candidates.

Stakeholder Impact

• Shareholders of Cerevel Therapeutics received $45.00 per share.
• Pfizer Inc. no longer holds shares in Cerevel Therapeutics.
• AbbVie now owns Cerevel Therapeutics as a wholly owned subsidiary.

Key Dates